ArticleBMC cancer2025
Clinical evaluation of a novel-developed clone 3E2 for the detection of PD-L1 expression status in lung adenocarcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDetecting programmed death-ligand 1 (PD-L1) expression helps identify patients likely to respond to PD-1/PD-L1 therapies. However, the high costs of PD-L1 assays, such as SP263 pharmDx, limit their widespread use, creating a need for cost-effective alternatives. This study evaluates the analytical performance and concordance of the newly developed 3E2 PD-L1 antibody with established clones in lung adenocarcinoma (LUAD).
methodsThe 3E2 monoclonal antibody was developed using the hybridoma technique. Its performance was compared with that of the SP263, Cell Signaling Technology (CST) E1L3N, and Abcam 28-8 clones using immunohistochemistry on 101 LUAD samples. Concordance was assessed using Bland-Altman plots, confusion matrices, and quantitative analyses. Survival analysis was performed to investigate the correlation between PD-L1 expression detected by the 3E2 clone and treatment outcomes in patients undergoing immunotherapy.
resultsAmong 30 PD-L1 monoclonal antibodies generated via hybridoma, the 3E2 clone showed high sensitivity and specificity for PD-L1 detection. It exhibited strong concordance with Abcam 28-8 in positive (placenta) and negative (normal stomach mucosa) control tissues, as well as non-small cell lung cancer and melanoma samples (accuracy: 90.1%, κ: 0.797). Moderate agreement was observed with CST E1L3N (accuracy: 69.8%, κ: 0.401) and SP263 (accuracy: 55.4%, κ: 0.262), with higher PD-L1 expression detected by E1L3N and SP263. Bland-Altman analysis showed minimal bias between 3E2 and 28-8. Survival analysis revealed that patients with PD-L1 expression ≥ 5% (detected by 3E2) had significantly better outcomes (p = 0.021).
conclusionsThe 3E2 antibody demonstrates high concordance with Abcam 28-8, offering a potential cost-effective alternative for PD-L1 detection with preliminary prognostic value in immunotherapy-treated LUAD patients. Further validation is required to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.